EMA Authorised: Eurneffy (epinephrine) — ALK-Abelló A/S

View source ↗

Summary

EMA authorised Eurneffy for the treatment of anaphylaxis; the marketing authorisation holder is ALK-Abelló A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaphylaxis

Drugs mentioned

• Eurneffy (epinephrine)

Snippet

Status: Authorised. Therapeutic area: Anaphylaxis. MAH: ALK-Abelló A/S. Decision date: 27/03/2026